Nurses, Patients Prefer Subcutaneous Rituximab Over IV


A recent study analyzed nurse and patient preference when it came to the administration of rituximab in patients with blood cancer.

Nurses, Patients Prefer Subcutaneous Rituximab Over IV

Nurses, Patients Prefer Subcutaneous Rituximab Over IV

Both patients and nurses prefered subcutaneous rituximab (Rituxan) administration over giving the drug intravenously, according to recent research presented at the 62nd ASH Annual Meeting and Exposition.

“Among nursing staff, time savings, convenience, and perceived patient preference contributed to the positive experience [of giving rituximab subcutaneously],” study author Mitul Gandhi, MD, said in his presentation. Gandhi is a medical oncologist at the Virginia Cancer Specialists.

Rituximab has FDA-approved indications to treat follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and chronic lymphocytic leukemia (CLL).

The researchers surveyed 29 patients (DLBCL, n = 12; FL, n = 13; CLL, n = 4) between July 2017 and April 2019. Average age was 69 years old, and the majority of patients had a preserved performance status and had received both IV and subcutaneous treatments.

Sixty-nine percent of patients said that they prefer subcutaneous rituximab. Common reasons cited included: less time spent in clinic (69% of respondents) and less emotional distress (41%).

Additionally, 62% of patients said that subcutaneous rituximab was very convenient, compared to 45% who responded the same about the IV method. Subcutaneous administration was shown to be easier, too, as only 28% of respondents said that it required caregiver assistance, compared to 45% of those with IV.

Fifty-eight percent of nurses reported that they prefer giving rituximab via IV, citing that it saves time, it’s convenient, and patients prefer it. More than half (52%) said that 1.5 to 2 hours could be saved with subcutaneous administration.

Regarding nurse characteristics, the majority were younger than 65 years old, had a year or more of clinical experience, and had a familiarity with both the IV and subcutaneous methods of giving rituximab.

“In conclusion, even though our study was limited by a small sample size, the majority of surveyed patients and nurses expressed a preference of subcutaneous rituximab over intravenous rituximab, with reduced clinic time as the main motivation for this preference,” Gandhi said.

So, nurses and other clinicians should discuss patient preferences — as well as the pros and cons of each method of administration – with their patients before deciding on a treatment regimen.

“This real-word data provides useful information regarding the administration of subcutaneous rituximab in a community oncology setting,” Gandhi said.

Related Videos
Elizabeth Aronson
Shivani Gopalsami
Donna Catamero
Verina on Tackling Neurological Toxicities From CAR T-Cell Therapy
Sherry Adkins Talks Primary Care Provider Communication Following CAR T-cell Therapy
Gretchen McNally Speaks to the Role of Oncology Nurses in the Opioid Epidemic
Related Content
© 2024 MJH Life Sciences

All rights reserved.